Is there still hesitancy towards SARS-CoV-2 vaccination among people with neurological disease- a survey of the NeuroCOVID-19 task force of the European Academy of Neurology.

Publication date: Feb 04, 2025

An online 3-item survey was sent to the European Academy of Neurology (EAN) community and inquired about the persistence of SARS-CoV-2 vaccination skepticism and the underlying thoughts and factors restricting vaccine use among patients with neurological conditions. We obtained 616 responses from 84 countries, predominantly from Europe. In the view of the treating neurologist, patients with multiple sclerosis (MS), neuroimmunological disorders (ND), and chronic neurological infections continued to have high levels of skepticism toward SARS-CoV-2 vaccination. Patients with MS/ND were quoted as the most hesitant group, with 60% of the respondents sharing this impression. The patient group perceived as most confident towards immunization against COVID-19 and with the lowest level of distrust towards the vaccine were those with sleep disorders. For all other conditions, perceived distrust ranged between 42 and 52%. Fear of adverse events of vaccination or disease reactivation was perceived by 87% of patients with MS/ND and more than 70% of patients with stroke/vascular neurology, neuromuscular disorders, chronic neurological infections, and peripheral neuropathy. Patients with sleep disorders (54%), autonomic disorders (46%), movement disorders (43%), and dementia (43%) were sensed as less fearful of vaccine-related adverse events. Despite the large body of evidence proving the efficacy and safety of SARS-CoV-2 vaccination, patients with certain neurological disorders still have a surprisingly high percentage of distrust and fear of adverse events. Our observations emphasize the importance of continuous evidence-based information delivery and patient education by treating neurologists.

Open Access PDF

Concepts Keywords
Dementia Autoimmune
Europe COVID-19
Neurologists Disease prevention
Stroke Multiple sclerosis
Vaccination Neurological disease
Public health
SARS-CoV-2
Vaccination hesitancy

Semantics

Type Source Name
disease MESH multiple sclerosis
disease MESH infections
disease MESH COVID-19
disease MESH sleep disorders
disease MESH stroke
disease MESH peripheral neuropathy
disease MESH autonomic disorders
disease MESH movement disorders
disease MESH dementia
disease MESH neurological disorders
disease MESH complications
drug DRUGBANK Trestolone
disease MESH drug interaction
disease MESH motor neuron disease
disease MESH sclerosis
disease MESH infectious diseases
disease IDO history
disease IDO hospital facility
disease MESH emergency
disease MESH cognitive disorders
disease MESH Epilepsy
drug DRUGBANK Coenzyme M
disease MESH idiopathic inflammatory myopathies
disease IDO infection
disease MESH chronic diseases
pathway REACTOME Immune System
drug DRUGBANK Silver
disease MESH influenza
disease MESH measles
pathway KEGG Measles
disease MESH interstitial lung diseases
disease MESH relapse
drug DRUGBANK Etoperidone
disease MESH physical barriers
pathway REACTOME Reproduction
disease MESH viral infections
disease MESH Neurological manifestations
disease MESH death
disease MESH comorbidity
disease MESH syndromes
disease MESH Respiratory diseases
disease MESH immune diseases
disease MESH rheumatic diseases
disease MESH Autoimmune diseases

Original Article

(Visited 1 times, 1 visits today)